GSK adds alli warning
This article was originally published in The Tan Sheet
Executive Summary
Following an FDA safety review of the weight-loss drug orlistat, GlaxoSmithKline adds to alli packaging a warning about "rare reports of liver injury in people taking orlistat," and cautions consumers to "stop use and ask a doctor if you develop itching, yellow eyes or skin, dark urine or loss of appetite," the Parsippany, N.J.-based firm announced May 26. FDA also approved a revised label for Xenical, the prescription-strength version of alli marketed by Roche, the agency said in a same day release. The warnings were added after an FDA review found 13 reports of severe liver injury with orlistat - only one of which was associated with alli (1"The Tan Sheet" Aug. 31, 2009). The agency did not confirm a cause-and-effect relationship between the drug and liver injury, but GSK said it "takes all adverse events reports seriously ... [and] wants people to have the information they need to choose the right weight-loss aid for their situation.
You may also be interested in...
FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
FDA's announcement it is investigating a possible risk of liver injury related to orlistat - the active ingredient in Roche Pharmaceuticals' prescription weight-loss drug Xenical and GlaxoSmithKline's OTC alli - could threaten short-term sales
MoCRA Stakeholders Reminded Registration Enforcement Begins 1 July: ‘Do Not Delay!’
The Independent Beauty Association urged stakeholders at its Cosmetic Convergence Symposium to take action to ensure they are meeting requirements of the Modernization of Cosmetics Regulation Act come 1 July, when FDA’s enforcement of the facility and product registration deadline begins. Presenters offered tips from companies that have already completed the process.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.